You are here: Industry Insights > Inhibitor

News List

FDA approves label update to sodium glucose co-transporter-2 (SGLT2) inhibitors europeanpharmaceuticalreview
March 19, 2020
Safety updates to labels of SGLT2 inhibitors will recommend temporary discontinuation of these medications before scheduled surgery, says the FDA.
Pulmatrix Announces Agreement with Lung Cancer Initiative americanpharmaceuticalreview
January 06, 2020
Pulmatrix has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson. Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended fo
Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk drugs
August 29, 2019
Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes...
SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events drugs
July 31, 2019
Initiation of therapy with sodium-glucose cotransporter-2 (SGLT-2) inhibitors for type 2 diabetes mellitus is not associated with an increased risk for...
Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors drugs
July 25, 2019
Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetic ketoacidosis (DKA) may occur after surgery even in patients...
AUM Biosciences to develop Inflection’s cancer therapy pharmaceutical-technology
July 19, 2019
Biotechnology firm AUM Biosciences has entered a global licence agreement for Inflection Biosciences’ series of PIM/PI3K/mTOR inhibitor molecules.
Syndax Announces FDA Clearance of IND Application for Targeted Menin Inhibitor americanpharmaceuticalreview
July 11, 2019
Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use drugs
June 03, 2019
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use.
First PI3K inhibitor for breast cancer approved by FDA europeanpharmaceuticalreview
May 30, 2019
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
IL-18 inhibitor drug holds great potential for inflammatory diseases europeanpharmaceuticalreview
April 26, 2019
An international team of researchers has identified the key role that IL-18 protein plays in Still’s disease, making it a prime candidate for IL-18 inhibitor drug that is proving promising in current trials.

Previous page 1 2 3 4 Next page